Resources for Patients and their Families

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Brief Summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Tracking Information
First Received DateMarch 12, 2013
Last Changed DateMarch 15, 2013
Start DateJanuary 2012
Actual Primary Completion DateMarch 2013
Primary Outcome Measures

Overall survival [Time Frame: 5 years]

Secondary Outcome Measures

Disease-Free survival [Time Frame: 5 years]

Descriptive Information
Study TypeObservational
  • Peritoneal Mesotheliomas
  • Procedure: Cytoreductive surgery and HIPEC
Study Arms / Comparison Groups0 / 1
Detailed Description

Observation of primary outcome:

- Overall Survival

- Disease-free survival

Influencing factors that will be observe:

- Sex

- Blood loss

- Time of surgery

- Number of resection and anastomosis

- Peritoneal Index (PI score)

- Cytoreductibility (CCR score)

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment19
AgesN/A - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Peritoneal mesothelioma

Exclusion Criteria:

- Non resectable disease

Administrative Information
Responsible PartyPrincipal Investigator
SponsorMaisonneuve-Rosemont Hospital
Verification DateMarch 2013
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Fall 2018 Mesothelioma Cancer Alliance Scholarship Winner Darwin Arias

Prognosis of Mesothelioma Without Treatment

Asbestos Is No Laughing Matter

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: